ASTROCYTE PHARMACEUTICALS INC.
AST-004, a small molecule pharmaceutical agent that enhances astrocyte mitochondrial function to provide neuroprotection in traumatic brain injury
- Sector
- Biotech
- Headquarters
- GROTON, CT
- Founded
- 2014
- Latest Form D
- $2.8M, Oct 2022
- Total capital
- $20.9M
- Federal grants
- $9.1M
- 9 awards · 2015–2025
- Rank in peer group#261 of 514
- Private capital raised
- $11.7M
- 3 Form D · last Oct 2022
- 48 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 13 pending · first 2020
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)$1.5M
- Private capital raisedForm D · SEC · 3rd filing$2.8M
- Private capital raisedForm D · SEC · 2nd filing$7.5M
- Federal grantHealth and Human S · Phase II · Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1.5M
- Federal grantHealth and Human S · Phase I · Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease$98K
- Federal grantHealth and Human S · Phase II · Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$3M
- Federal grantHealth and Human S · Phase II · Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.$1.5M
- Private capital raisedForm D · SEC · 1st filing$1.4M
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase I · Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease$200K
- Federal grantHealth and Human S · Phase I · Astrocyte Activation By Small Molecule P2Y1 Agonists For Treatment Of Tbi$251K
- Federal grantHealth and Human S · Phase I · Astrocyte Activation By Small Molecule P2Y1 Agonists For Treatment Of Tbi$672K
- Federal grantHealth and Human S · Phase I · Astrocyte Activation By Small Molecule P2Y1 Agonists For Treatment Of Tbi$420K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
19months
from ASTROCYTE PHARMACEUTICALS INC.’s first federal award to its first private round.
- First federal award · Sep 2015
- Health and Human S · $420K
- First Form D · Apr 2017
- $1.4M · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- James D. LechleiterResearcherDirectorLinked by $1.6M in grants as PI
- Christine S. GallagherDirectorNamed in SEC Form D filings
- Jackson S. StreeterDirectorNamed in SEC Form D filings
- Jeffrey ArnoldDirectorNamed in SEC Form D filings
- Jeffrey IvesDirectorNamed in SEC Form D filings
- William S. KorinekExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 15- PendingFast-dissolving Dosage Forms And Uses ThereofUSPTOApplication 19126330
- PendingMethods Of Treating Neurological And Cardiovascular ConditionsUSPTOApplication 18711834
- GrantedPolymorphic Compounds And Uses ThereofUSPTOUS 11,324,769
Show all 15 patent records
- Fast-dissolving Dosage Forms And Uses ThereofJun 4, 2026 · Application 19126330Pending
- Methods Of Treating Neurological And Cardiovascular ConditionsJun 5, 2025 · Application 18711834Pending
- Polymorphic Compounds And Uses ThereofMay 10, 2022 · US 11,324,769Granted
- Polymorphic Compounds And Uses ThereofSep 8, 2020 · US 10,765,693Granted
- Fast-dissolving Dosage Forms And Uses ThereofApplication 63521540Pending
- Methods Of Treating Neurological And Cardiovascular ConditionsApplication PCTUS2022050743Pending
- Compositions For Intravenous AdministrationApplication 63422292Pending
- Fast-dissolving Dosage Forms And Uses ThereofApplication 63422279Pending
- Methods Of Treating Neurological And Cardiovascular ConditionsApplication 63264424Pending
- Polymorphic Compounds And Uses ThereofApplication PCTUS2019053076Pending
- Polymorphic Compounds And Uses ThereofApplication 62736979Pending
- Compositions For Intravenous AdministrationApplication 19126309Pending
- Fast-dissolving Dosage Forms And Uses ThereofApplication PCTUS2023036734Pending
- Compositions For Intravenous AdministrationApplication PCTUS2023036747Pending
- Compositions For Intravenous AdministrationApplication 63521523Pending
Related companies, and why
- VasaMetrixSimilar federal contract value in Biotech · null in contracts
- SimBioSys, Inc.Similar federal contract value in Biotech · null in contracts
- C4 TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Soteria Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NATURA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- AMIDEBIO, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .